Literature DB >> 25312513

Polymorphisms of DNA repair genes are related to the pathogenesis of myelodysplastic syndrome.

Howard Lopes Ribeiro1,2, Roberta Taiane Germano de Oliveira2, Allan Rodrigo Soares Maia1,2, Luiz Ivando Pires Ferreira Filho1,2, Juliana Cordeiro de Sousa1,2, Fabiola Fernandes Heredia2, Silvia Maria Meira Magalhães1,2, Ronald Feitosa Pinheiro1,3,2.   

Abstract

Some studies show that alterations in DNA repair genes polymorphisms are associated with the pathogenesis and susceptibility of Myelodysplastic Syndrome (MDS). We genotyped 60 MDS patients for six DNA repair gene polymorphisms: BRCA1 rs4793191, BRCA2 rs9567623, RAD51 rs1801320, XRCC5 rs3835, XRCC6 rs2267437 and LIG4 rs1805388. The G/C heterozygote genotype of rs1801320 polymorphism was associated with a decreased chance of developing MDS (p = 0.05). Additionally, the G/G homozygous genotype was associated with the presence of one cytopenia in whole blood. The genotype C/G and CG + GG of the rs2267437 polymorphism was associated with normal karyotype (p = 0.010) and bone marrow cellularity normocellular + hypercellular (p = 0.023). We found that the A/G heterozygous genotype of the rs3835 polymorphism is associated with decreased chance of developing MDS (p < 0.001). These results support the importance of RAD51, XRCC5 and XRCC6 genes polymorphisms in the maintenance of genomic stability promoting a better understanding of the genesis and etiology of MDS.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  DNA repair; cytogenetics; homologous recombination mechanism; myelodysplastic syndrome; non-homologous end joining mechanism

Mesh:

Year:  2014        PMID: 25312513     DOI: 10.1002/hon.2175

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  5 in total

1.  Can synthetic lethality approach be used with DNA repair genes for primary and secondary MDS?

Authors:  Howard Lopes Ribeiro Junior; Roberta Taiane Germano de Oliveira; Daniela de Paula Borges; Marília Braga Costa; Izabelle Rocha Farias; Antônio Wesley Araújo Dos Santos; Silvia Maria Meira Magalhães; Ronald Feitosa Pinheiro
Journal:  Med Oncol       Date:  2019-10-30       Impact factor: 3.064

2.  Pediatric MDS and bone marrow failure-associated germline mutations in SAMD9 and SAMD9L impair multiple pathways in primary hematopoietic cells.

Authors:  Melvin E Thomas; Sherif Abdelhamed; Ryan Hiltenbrand; Jason R Schwartz; Sadie Miki Sakurada; Michael Walsh; Guangchun Song; Jing Ma; Shondra M Pruett-Miller; Jeffery M Klco
Journal:  Leukemia       Date:  2021-03-17       Impact factor: 12.883

3.  A Phase I trial of talazoparib in patients with advanced hematologic malignancies.

Authors:  Ajay K Gopal; Rakesh Popat; Ryan J Mattison; Tobias Menne; Adrian Bloor; Terry Gaymes; Asim Khwaja; Mark Juckett; Ying Chen; Matthew J Cotter; Ghulam J Mufti
Journal:  Int J Hematol Oncol       Date:  2021-10-22

Review 4.  Applying a Weight-of-Evidence Approach to Evaluate Relevance of Molecular Landscapes in the Exposure-Disease Paradigm.

Authors:  Sherilyn A Gross; Kristen M Fedak
Journal:  Biomed Res Int       Date:  2015-08-03       Impact factor: 3.411

5.  Polymorphisms of homologous recombination RAD51, RAD51B, XRCC2, and XRCC3 genes and the risk of prostate cancer.

Authors:  Maria Nowacka-Zawisza; Ewelina Wiśnik; Andrzej Wasilewski; Milena Skowrońska; Ewa Forma; Magdalena Bryś; Waldemar Różański; Wanda M Krajewska
Journal:  Anal Cell Pathol (Amst)       Date:  2015-08-03       Impact factor: 2.916

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.